BRAIN Biotech AG: Additional Differentiated Genome-Editing Nuclease: BRAIN-Metagenome-Cas 01 (BMC01)

Additional Differentiated Genome-Editing Nuclease: BRAIN-Metagenome-Cas 01 (BMC01)

Zwingenberg, Germany, December 8th, 2021. BRAIN Biotech AG ("BRAIN") is extending its proprietary genome-editing toolbox with the addition of BRAIN-Metagenome-Cas 01 (BMC01) nuclease. In comparison to the publically recognized BRAIN-Engineered Cas (BEC), the BMC01 nuclease has a differentiated protein structure and mode of action to target DNA. BMC01 has already been filed for IP protection. This additional nuclease will extend BRAIN's proprietary genome editing competence and further enhance the overall economic potential of the platform, in case patent protection is granted.

Notifying person:

Michael Schneiders, Head of IR & Sustainability

BRAIN Biotech AG
Darmstädter Str. 34-36, 64673 Zwingenberg, Germany
www.brain-biotech.com

Investor Relations Office
Tel.: +49-(0)-6251-9331-0
Fax: +49-(0)-6251-9331-11
E-Mail: [email protected]

End of ad hoc announcement